Iede, K., Yamada, T., Kato, R., Ueda, M., Tsuda, Y., Nakashima, S., . . . Tominaga, S. (2020). Predictive implications of decreased CA19‐9 at 8 weeks during nab‐paclitaxel plus gemcitabine for the induction of second‐line chemotherapy for patients with advanced pancreatic cancer. Cancer Rep (Hoboken).
Style de citation ChicagoIede, Kiyotsugu, et al. "Predictive Implications of Decreased CA19‐9 At 8 weeks During Nab‐paclitaxel Plus Gemcitabine for the Induction of Second‐line Chemotherapy for Patients With Advanced Pancreatic Cancer." Cancer Rep (Hoboken) 2020.
Style de citation MLAIede, Kiyotsugu, et al. "Predictive Implications of Decreased CA19‐9 At 8 weeks During Nab‐paclitaxel Plus Gemcitabine for the Induction of Second‐line Chemotherapy for Patients With Advanced Pancreatic Cancer." Cancer Rep (Hoboken) 2020.